Invivyd, Inc.
VMS063
Measles
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews VMS063 for Measles around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 12h ago
“Initiated outreach to Expect initial proof-of-concept Expect IND-readiness FDA to discuss potential data in early treatment setting, by year-end 2026 regulatory pathways subject to regulatory feedback”